JP6766040B2 - 視覚および可聴インジケータを備える薬剤注射装置 - Google Patents

視覚および可聴インジケータを備える薬剤注射装置 Download PDF

Info

Publication number
JP6766040B2
JP6766040B2 JP2017519830A JP2017519830A JP6766040B2 JP 6766040 B2 JP6766040 B2 JP 6766040B2 JP 2017519830 A JP2017519830 A JP 2017519830A JP 2017519830 A JP2017519830 A JP 2017519830A JP 6766040 B2 JP6766040 B2 JP 6766040B2
Authority
JP
Japan
Prior art keywords
housing
drug
needle guard
needle
color
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017519830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530817A (ja
JP2017530817A5 (cg-RX-API-DMAC7.html
Inventor
シュルツ，ピーター・ブイ
フォーク，クリストファー・アール
ムスリンガー，ジークリット
ウダガワ，マサミチ
エバンス，モリー
ガオ，リン
ニュージェント，リサ
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2017530817A publication Critical patent/JP2017530817A/ja
Publication of JP2017530817A5 publication Critical patent/JP2017530817A5/ja
Application granted granted Critical
Publication of JP6766040B2 publication Critical patent/JP6766040B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321—Means for protection against accidental injuries by used needles
    • A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
    • A61M5/3257—Semi-automatic sleeve extension, i.e. in which triggering of the sleeve extension requires a deliberate action by the user, e.g. manual release of spring-biased extension means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B50/00—Containers, covers, furniture or holders specially adapted for surgical or diagnostic appliances or instruments, e.g. sterile covers
    • A61B50/30—Containers specially adapted for packaging, protecting, dispensing, collecting or disposing of surgical or diagnostic appliances or instruments
    • A61B50/33—Trays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/3129—Syringe barrels
    • A61M5/3134—Syringe barrels characterised by constructional features of the distal end, i.e. end closest to the tip of the needle cannula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321—Means for protection against accidental injuries by used needles
    • A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
    • A61M5/3245—Constructional features thereof, e.g. to improve manipulation or functioning
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/50—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
    • A61M5/5086—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile for indicating if defective, used, tampered with or unsterile
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321—Means for protection against accidental injuries by used needles
    • A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
    • A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
    • A61M2005/3261—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user triggered by radial deflection of the anchoring parts between sleeve and syringe barrel, e.g. spreading of sleeve retaining hooks having slanted surfaces by engagement with conically shaped collet of the piston rod during the last portion of the injection stroke of the plunger
    • A61M2005/3263—Trigger provided at the distal end, i.e. syringe end for mounting a needle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321—Means for protection against accidental injuries by used needles
    • A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
    • A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
    • A61M2005/3267—Biased sleeves where the needle is uncovered by insertion of the needle into a patient's body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Environmental & Geological Engineering (AREA)
  • Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Details Of Rigid Or Semi-Rigid Containers (AREA)
JP2017519830A 2014-10-14 2015-10-14 視覚および可聴インジケータを備える薬剤注射装置 Active JP6766040B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462063737P 2014-10-14 2014-10-14
US62/063,737 2014-10-14
PCT/US2015/055523 WO2016061220A2 (en) 2014-10-14 2015-10-14 Drug injection device with visual and audio indicators

Publications (3)

Publication Number Publication Date
JP2017530817A JP2017530817A (ja) 2017-10-19
JP2017530817A5 JP2017530817A5 (cg-RX-API-DMAC7.html) 2018-11-15
JP6766040B2 true JP6766040B2 (ja) 2020-10-07

Family

ID=54347920

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017519830A Active JP6766040B2 (ja) 2014-10-14 2015-10-14 視覚および可聴インジケータを備える薬剤注射装置

Country Status (7)

Country Link
US (3) US10695506B2 (cg-RX-API-DMAC7.html)
EP (2) EP3943135B1 (cg-RX-API-DMAC7.html)
JP (1) JP6766040B2 (cg-RX-API-DMAC7.html)
AU (1) AU2015332557B2 (cg-RX-API-DMAC7.html)
CA (1) CA2957960C (cg-RX-API-DMAC7.html)
MX (2) MX392725B (cg-RX-API-DMAC7.html)
WO (1) WO2016061220A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2658588A1 (en) * 2010-12-30 2013-11-06 Meridian Medical Technologies, Inc. Slip-resistant autoinjectors
CN107683158B (zh) 2015-06-04 2021-05-14 麦迪麦珀医疗工程有限公司 用于药物释放装置的筒插入
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
CN109843357B (zh) * 2016-10-25 2023-04-28 赛诺菲-安万特德国有限公司 状态指示器和带状态指示器的药物递送装置以及药物递送装置的制造方法
EP3606579B1 (en) 2017-04-06 2023-09-06 West Pharmaceutical Services, Inc. Injector with ready to use indicator
CN110678215B (zh) 2017-05-25 2022-02-25 西部制药服务有限公司 使用nfc通信和电容检测的智能注射器
JP2019107216A (ja) * 2017-12-18 2019-07-04 エイワイファーマ株式会社 リウマチ用ペン型注射器の包装袋
JP7402799B2 (ja) 2017-12-22 2023-12-21 ウェスト ファーマ サービシーズ イスラエル リミテッド サイズの異なるカートリッジを利用可能な注射器
CA3155912A1 (en) 2019-09-25 2021-04-01 Janssen Pharmaceuticals, Inc. Interconnection of drug administration systems
CA3152217A1 (en) * 2019-10-08 2021-04-15 Amgen Inc. Temperature indicator for drug delivery device
CN115379870A (zh) * 2020-04-03 2022-11-22 赛诺菲 注射器装置
WO2025027979A1 (ja) * 2023-08-02 2025-02-06 テルモ株式会社 薬液投与装置
WO2025034656A2 (en) * 2023-08-08 2025-02-13 Amgen Inc. Drug delivery device having a needle shield with visual feedback

Family Cites Families (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
KR100221066B1 (ko) 1989-10-13 1999-10-01 스튜어트 엘.왓트 에리트로포이에틴 유사체와 그를 포함하는 제약학적 조성물
US5984899A (en) * 1993-02-11 1999-11-16 Beech Medical Products, Inc. Needle protector device having a lockable protective cover which is unlockable during actuation
IL192290A0 (en) 1993-08-17 2008-12-29 Kirin Amgen Inc Erythropoietin analogs
US6562596B1 (en) 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
ATE306930T1 (de) 1994-08-12 2005-11-15 Immunomedics Inc Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
CA2296770A1 (en) 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
PT986644E (pt) 1997-07-23 2007-01-31 Roche Diagnostics Gmbh Preparação de eritropoietina por activação genética endógena com promotores virais
WO1999011306A1 (en) * 1997-09-03 1999-03-11 Safer Sleep Limited Coding of syringes to monitor their use
US6030086A (en) 1998-03-02 2000-02-29 Becton, Dickinson And Company Flash tube reflector with arc guide
US6310078B1 (en) 1998-04-20 2001-10-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as erythropoietin mimetics
US6548653B1 (en) 1998-06-15 2003-04-15 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
US20050181482A1 (en) 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
HK1040944B (en) 1998-10-23 2007-09-07 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
EP1124961B9 (en) 1998-10-23 2010-07-21 Kirin-Amgen Inc. Thrombopoietic compounds
IL143266A0 (en) 1998-11-27 2002-04-21 Darwin Discovery Ltd Transforming growth factor-beta binding proteins and pharmaceutical compositions for increasing bone mineral content utilizing the same
EP1006184A1 (en) 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
EP1169352A4 (en) 1999-04-14 2005-05-04 Smithkline Beecham Corp ANTIBODY AGAINST THE ERYTHROPOIETIN RECEPTOR
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
WO2001031007A2 (en) 1999-10-22 2001-05-03 Millennium Pharmaceuticals, Inc. Nucleic acid molecules derived from rat brain and programmed cell death models
AU2154401A (en) 1999-11-12 2001-05-30 Merck Patent Gmbh Erythropoietin forms with improved properties
US20050202538A1 (en) 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
BRPI0107736B8 (pt) 2000-01-21 2021-05-25 Biovex Ltd cepa hsv1 js1, composição farmacêutica, e, uso de uma cepa hsv1 js1
AUPQ599700A0 (en) 2000-03-03 2000-03-23 Super Internet Site System Pty Ltd On-line geographical directory
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU5551601A (en) 2000-04-21 2001-11-07 Amgen Inc Methods and compositions for the prevention and treatment of anemia
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
GB2366705B (en) 2000-08-29 2004-07-14 Motorola Inc Communications system, communications unit and method of operation
MXPA03001469A (es) 2000-09-08 2004-12-13 Gryphon Therapeutics Inc Proteinas sinteticas estimulantes de la eritropoyesis.
US7271689B1 (en) 2000-11-22 2007-09-18 Fonar Corporation Magnet structure
EP1345628B1 (en) 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Conjugates of erythropoietin (epo) with polyethylene glycol (peg)
GEP20084484B (en) 2001-01-05 2008-09-25 Pfizer Antibodies to insulin-like growth factor i receptor
CA2443373A1 (en) 2001-04-04 2002-10-31 Genodyssee New polynucleotides and polypeptides of the erythropoietin gene
EP1921088B1 (en) 2001-05-11 2014-10-08 Amgen Inc. Peptides and related molecules that bind to tall-1
TR201809008T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
EP1425389B1 (en) 2001-08-23 2011-11-02 Genmab A/S Human antibodies specific for interleukin 15 (il-15)
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
WO2003055526A2 (en) 2001-12-21 2003-07-10 Maxygen Aps Erythropoietin conjugates
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
AU2003216748B2 (en) 2002-01-18 2009-07-16 Pierre Fabre Medicament Novel anti-IGF-IR antibodies and uses thereof
GB0202252D0 (en) 2002-01-31 2002-03-20 Oxford Biomedica Ltd Anemia
EP1470232A1 (en) 2002-01-31 2004-10-27 Oxford Biomedica (UK) Limited Physiologically regulated erythropoietin-expressing vector for the treatment of anaemia
EP1492878B1 (en) 2002-03-26 2007-05-30 Lek Pharmaceutical and Chemical Co. D.D. Process for the preparation of a desired erythropoietin glyco-isoform profile
WO2003084477A2 (en) 2002-03-29 2003-10-16 Centocor, Inc. Mammalian cdr mimetibodies, compositions, methods and uses
DE60328092D1 (de) 2002-03-29 2009-08-06 Kumiai Chemical Industry Co Acetolactatsynthase codierende gene
CA2485365A1 (en) 2002-05-13 2003-11-20 Modigenetech Ltd. Ctp-extended erythropoietin
MXPA04011624A (es) 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
JP2006504406A (ja) 2002-06-28 2006-02-09 セントカー・インコーポレーテツド 哺乳動物のｃｈ１欠失ミメティボディ、組成物、方法および使用
US7241733B2 (en) 2002-06-28 2007-07-10 Centocor, Inc. Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
WO2004009627A1 (en) 2002-07-19 2004-01-29 Cangene Corporation Pegylated erythropoietic compounds
WO2004018667A1 (ja) 2002-08-26 2004-03-04 Kirin Beer Kabushiki Kaisha ペプチド及びこれを含む医薬
JP4317817B2 (ja) 2002-09-06 2009-08-19 アムジェン インコーポレイテッド 治療用ヒト抗ｉｌ−１ｒ１モノクローナル抗体
WO2005025606A1 (en) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
CA2496317C (en) 2002-09-11 2014-02-18 Fresenius Kabi Deutschland Gmbh Method of producing hydroxyalkyl starch derivatives
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
US20040071694A1 (en) 2002-10-14 2004-04-15 Devries Peter J. Erythropoietin receptor binding antibodies
TWI320716B (en) 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
WO2004034988A2 (en) 2002-10-16 2004-04-29 Amgen Inc. Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
US20040091961A1 (en) 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
EA009056B1 (ru) 2002-12-20 2007-10-26 Амген, Инк. Связывающие агенты, ингибирующие миостатин
US20040167476A1 (en) * 2003-02-24 2004-08-26 Westbye Lars Tommy Tamper evident needle guard for syringes
EP1603948A1 (en) 2003-03-14 2005-12-14 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
JP4473257B2 (ja) 2003-04-02 2010-06-02 エフ．ホフマン−ラ ロシュ アーゲー インスリン様成長因子ｉ受容体に対する抗体及びその使用
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CN100441595C (zh) 2003-05-12 2008-12-10 阿费麦克斯公司 结合红细胞生成素受体的新肽
AU2004238869B2 (en) 2003-05-12 2009-06-25 Affymax, Inc. Novel poly(ethylene glycol) modified compounds and uses thereof
PT1625156E (pt) 2003-05-12 2013-01-09 Affymax Inc Novos péptidos que se fixam ao receptor da eritropoietina
US7074755B2 (en) 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
US6995245B2 (en) 2003-05-30 2006-02-07 Centocor, Inc. Formation of novel erythropoietin conjugates using transglutaminase
WO2005001136A1 (en) 2003-06-04 2005-01-06 Irm Llc Methods and compositions for modulating erythropoietin expression
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
TWI382031B (zh) 2003-07-15 2013-01-11 Amgen Inc 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體
CN103880955A (zh) 2003-07-18 2014-06-25 安姆根有限公司 肝细胞生长因子的特异性结合物
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
US7169128B2 (en) * 2003-08-04 2007-01-30 Bioquiddity, Inc. Multichannel fluid delivery device
JP2007512001A (ja) 2003-08-28 2007-05-17 バイオレクシス ファーマシューティカル コーポレイション Ｅｐｏミメティックペプチドおよび融合タンパク質
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
WO2005081687A2 (en) 2003-09-30 2005-09-09 Centocor, Inc. Human hinge core mimetibodies, compositions, methods and uses
TWI356064B (en) 2003-11-07 2012-01-11 Immunex Corp Antibodies that bind interleukin-4 receptor
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
NZ547168A (en) 2003-11-24 2010-05-28 Biogenerix Ag Glycopegylated erythropoietin
WO2005058967A2 (en) 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
EP1548031A1 (en) 2003-12-22 2005-06-29 Dubai Genetics FZ-LLC Nature-identical erythropoietin
AU2004311796A1 (en) 2003-12-31 2005-07-21 Centocor, Inc. Novel recombinant proteins with N-terminal free thiol
BRPI0417916A (pt) 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
US7423139B2 (en) 2004-01-20 2008-09-09 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5′-UTR
US20050187158A1 (en) 2004-01-22 2005-08-25 Ranby Mats G. Pharmaceutical composition
WO2005084711A1 (en) 2004-03-02 2005-09-15 Chengdu Institute Of Biological Products A pegylated recombinant erythropoietin that has in vivo activity
AR048918A1 (es) 2004-03-11 2006-06-14 Fresenius Kabi De Gmbh Conjugados de almidon de hidroxietilo y eritropoyetina
CA2560889A1 (en) 2004-03-23 2005-10-13 Sanjay D. Khare Monoclonal antibodies specific for human ox40l (cd 134l)
US20050227289A1 (en) 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
US20080194475A1 (en) 2004-04-23 2008-08-14 Andrew Buchanan Erythropoietin Protein Variants
EP1781697B1 (en) 2004-07-07 2009-04-22 H.Lundbeck A/S Novel carbamylated epo and method for its production
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
WO2006029094A2 (en) 2004-09-02 2006-03-16 Xencor, Inc. Erythropoietin derivatives with altered immunogenicity
CA2586915A1 (en) 2004-11-10 2006-05-18 Aplagen Gmbh Molecules which promote hematopoiesis
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
US7390319B2 (en) * 2005-04-13 2008-06-24 Steven Friedman Automatic needle injector having safety triggering mechanism
JP5222722B2 (ja) 2005-04-20 2013-06-26 ベクトン・ディキンソン・フランス・エス．エー．エス． 注入セットおよび注入補助装置
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
PL2100614T3 (pl) 2005-06-17 2014-02-28 Imclone Llc Przeciwciała przeciwko PDGFR alfa do zastosowania w leczeniu guzów nowotworowych
WO2007000328A1 (en) 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
EP2388276A3 (en) 2005-07-18 2013-11-27 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
US7851438B2 (en) 2006-05-19 2010-12-14 GlycoFi, Incorporated Erythropoietin compositions
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
CA2667869A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
US20100041102A1 (en) 2006-11-07 2010-02-18 Ayesha Sitlani Antagonists of pcsk9
EP2106261A4 (en) 2006-11-07 2010-05-26 Merck Sharp & Dohme ANTAGONISTS OF PCSK9
WO2008057457A2 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
CA2681428A1 (en) 2007-04-13 2008-10-23 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (pcsk9)
PE20090768A1 (es) 2007-06-20 2009-07-09 Irm Llc Metodos y composiciones para el tratamiento de enfermedades alergicas
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
SG2013014352A (en) 2007-10-26 2014-09-26 Merck Sharp & Dohme Anti-pcsk9 and methods for treating lipid and cholesterol disorders
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP2480576A4 (en) 2009-09-25 2013-04-10 Merck Sharp & Dohme PCSK9 ANTAGONISTS
CA2777542A1 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
EP2493505A4 (en) 2009-10-30 2013-06-12 Merck Sharp & Dohme Ax1 and ax189 pcsk9 antagonists and variants
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
SG183867A1 (en) 2010-03-11 2012-10-30 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
MX2013007168A (es) 2010-12-22 2013-11-04 Genentech Inc Anticuerpo anti-pcsk9 y metodos de uso.
WO2012101252A2 (en) 2011-01-28 2012-08-02 Sanofi Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
EA201391157A1 (ru) 2011-02-11 2014-02-28 АйАрЭм ЭлЭлСи Антагонисты pcsk9
EP2699283A2 (en) * 2011-04-21 2014-02-26 Sanofi-Aventis Deutschland GmbH Medicated module with automatic reservoir engagement and lock mechanism
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
EP2572741A1 (en) * 2011-09-23 2013-03-27 Sanofi-Aventis Deutschland GmbH Medicament delivery device and actuation mechanism for a drug delivery device
CN104394909B (zh) * 2012-05-25 2017-03-29 阿普塔尔法国简易股份公司 自动注射器
EP2716318A1 (en) * 2012-10-04 2014-04-09 Sanofi-Aventis Deutschland GmbH Medicament delivery device with medicament delivery initiation indicator
EP2719414A1 (en) * 2012-10-15 2014-04-16 Sanofi-Aventis Deutschland GmbH Medicament delivery device with use indicator
WO2014060563A2 (en) * 2012-10-17 2014-04-24 Oval Medical Technologies Limited Automatic drug delivery devices
US9179260B2 (en) * 2012-12-03 2015-11-03 Mylan Inc. Medicament information system and method
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
US20140257200A1 (en) * 2013-03-11 2014-09-11 Judith Auerbach Safety system for a needle retaining device
MX380644B (es) 2013-03-14 2025-03-12 Amgen Inc Composiciones y metodos de variantes de inhibidor tisular de la metaloproteinasa tipo tres (timp-3).
US20140274874A1 (en) 2013-03-14 2014-09-18 Amgen Inc. Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods

Also Published As

Publication number Publication date
EP3943135A2 (en) 2022-01-26
AU2015332557A1 (en) 2017-03-02
EP3206739B1 (en) 2021-12-01
EP3943135B1 (en) 2025-09-24
US10695506B2 (en) 2020-06-30
JP2017530817A (ja) 2017-10-19
MX392725B (es) 2025-03-24
MX2021014323A (es) 2023-02-02
US11633548B2 (en) 2023-04-25
US20170224934A1 (en) 2017-08-10
AU2015332557B2 (en) 2020-05-14
CA2957960C (en) 2023-08-22
US12303674B2 (en) 2025-05-20
CA2957960A1 (en) 2016-04-21
US20230226284A1 (en) 2023-07-20
EP3943135A3 (en) 2022-06-29
WO2016061220A2 (en) 2016-04-21
US20200390982A1 (en) 2020-12-17
EP3206739A2 (en) 2017-08-23
WO2016061220A3 (en) 2016-06-09
MX2017004836A (es) 2017-07-20

Similar Documents

Publication Publication Date Title
US12303674B2 (en) Drug injection device with visual and audio indicators
JP7295900B2 (ja) 自動式注射装置
US20220273878A1 (en) Drug delivery device with live button or user interface field
US11385140B2 (en) Testing assemblies and testing methods for drug delivery devices
JP2023145514A (ja) 薬物送達デバイスの扉ラッチ機構
JP2019516626A (ja) バイアル・スリーブ組立体
JP2020503976A (ja) 注入デバイスならびに関連する使用および組立方法
JP7608439B2 (ja) 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
AU2020314824B2 (en) Drug delivery system with adjustable injection time and method of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181001

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200713

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200916

R150 Certificate of patent or registration of utility model

Ref document number: 6766040

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250